News

Novartis plans to assume complete control over Alcon Laboratories in a two-step process that some analysts and some members of Alcon's board of directors are challenging for its fairness under U.S. and Swiss merger laws.

Glaucoma and ocular hypertension can effectively be treated topically with IOP-lowering drops.

In his work, Mr. De Gennaro is often asked to review optical dispensary financial statements, which reveal much about how efficiently a dispensary runs as a business.

A new auto tonometer with corneal response technology features corneal compensated IOP, a pressure measurement significantly less affected by the cornea than with other methods of tonometry.

A dentist, aged 48 years, was referred for evaluation and management of loss of correctable acuity, disabling glare, and loss of binocular stereopsis following a series of complicated surgical procedures in his left eye.

Results of a published case series reaffirm the safety of magnetic resonance imaging studies in patients with miniature glaucoma shunt.

The latest generation of photochromic lenses is designed to deliver a combination of high performance and compatibility with all premium lens materials.

InSite Vision Inc. has announced plans to study ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery, in clinical trials pending the completion of investigational new drug-enabling toxicology studies in the first half of this year.

ThromboGenics NV expects to present the results of two phase III trials evaluating microplasmin for the non-surgical treatment of eye disease later this year.

BTG plc has licensed to Allergan exclusive worldwide rights to develop products for eye diseases and conditions using BTG's drug delivery system (ReGel).

Gregory L. Skuta, MD, has been named president and chief executive officer (CEO) of the Dean McGee Eye Institute, succeeding David W. Parke II, MD, who was appointed executive vice president and CEO of the American Academy of Ophthalmology in San Francisco in 2009.

Tom Hejkal, MD, PhD, became the McGaw Memorial Chairman of the Department of Ophthalmology and Visual Sciences at University of Nebraska Medical Center on Dec. 1.

ISTA Pharmaceuticals Inc. has submitted a supplemental new drug application to the FDA for bromfenac ophthalmic solution dosed once-daily as a treatment for ocular inflammation and pain following cataract surgery.

Bausch & Lomb has announced the launch of the first aberration-free accommodating IOL with aspheric optics (Crystalens AO) to cataract surgeons worldwide.

Alcon Laboratories Inc. plans to acquire Optonol Ltd. by the end of first quarter.

TLC Vision Corp. and two of its wholly owned subsidiaries, TLC Vision (USA) Corp. and TLC Management Services, are restructuring their debt through a pre-arranged Chapter 11 bankruptcy proceeding.

Novartis AG has exercised its option to purchase the remaining shares in Alcon Laboratories Inc. owned by Nestle S.A. at a weighted average price of $180 per share in cash, according to prepared statement from Alcon.

An angle-supported phakic lens had a minimal effect on corneal endothelial cell health in patients followed up to 4 years after implantation.

A microkeratome is a safe and effective alternative to femtosecond laser for flap creation when performing sub-Bowman's keratomileusis, and the mechanical device offers a number of advantages as well.

The latest version of an accommodating IOL provides increased depth of field for better near vision performance than predecessor versions.

With this issue of Ophthalmology Times, the publication launches a new series that will feature different institutions around the country.

Preliminary results from a study investigating use of a intraoperative wavefront aberrometer indicate that it accurately measures the refraction in aphakic eyes and translates the data into IOL power to enable excellent outcomes after cataract surgery.

A corneal inlay improves near and intermediate vision without compromising functional distance vision.

A refractive procedure 15 years in the making uses microwave technology to reshape the cornea.

After decades of giving pharmaceutical treatment options for glaucoma, Alcon Laboratories plans to add a surgical treatment option by acquiring Optonol Ltd.

Accumulating results from studies investigating a light-adjustable IOL indicate this technology can afford precise postoperative control over refractive outcomes.

Early results are encouraging using the 500 kHz femtosecond laser in a reverse-cut technique to prepare DSEK donor tissue.

When first treating patients with acute chemical burns of the eye, one expert advises use of a buffering solution for irrigation rather than isotonic saline.